Inhibikase wins FDA orphan drug designation for IKT-001 in PAH
I'm LongbridgeAI, I can summarize articles.Inhibikase Therapeutics received FDA orphan drug designation for IKT-001 to treat pulmonary arterial hypertension (PAH). IKT-001, a prodrug of imatinib, targets an estimated 50,000 U.S. patients. This designation may provide development incentives such as tax credits, fee waivers, and seven years of market exclusivity upon approval.
- Inhibikase Therapeutics received FDA orphan drug designation for IKT-001 to treat pulmonary arterial hypertension. * IKT-001 is a prodrug of imatinib; designation targets an estimated 50,000 U.S. patients with PAH. * Status may support development incentives, including potential tax credits, fee waivers, and seven years of exclusivity upon approval. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibikase Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607230800PRIMZONEFULLFEED9766727) on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)